A team of researchers headed by Dr. Ignatia Van den Veyver have shown that mutations in an early embryonic development gene may provide some clue to unexplained female infertility and recurrent pregnancy loss. The study was published in Scientific Reports, a member of the Nature family of journals.
Researchers at the NRI have identified a novel role for ABL1, a known tumorigenic gene, in a new developmental disorder. The study was published in the journal, Nature Genetics journal and was led by Drs. Christian Schaaf, Yaping Yang and Xia Wang, faculty at the Baylor College of Medicine.
A collaborative study spearheaded by Dr. Huda Zoghbi shows that loss of Ataxin1-Capicua (ATXN1-CIC) complex causes a previously unidentified neurodevelopmental disorder in mice and humans. This discovery, published in Nature Genetics, perfectly illustrates how meticulous studies in animal models can lead to serendipitous discovery of new syndromes, which helps patients and their families to receive accurate diagnosis and more importantly, gives them hope for possible future treatments.
In a review published in the journal Disease Models & Mechanisms, Drs. Joshua Shulman and Michael Wangler argue that fruit flies are one of the best biological tools to decipher complex genetic disorders. The authors urge for closer dialogue and collaborations between human geneticists, who typically lead GWAS studies, and basic fly biologists who are expert in the dissection of genetic mechanisms.
A large collaborative study led by Dr. Joshua Shulman and Dr. Peter Heutink has revealed five strong candidate genes for Parkinson’s disease. In this one-of-a-kind study sponsored by the International Parkinson’s Disease Genomics Consortium (IPDGC), researchers performed whole-exome sequencing and functional analysis of 1148 unrelated Parkinson’s disease cases, the largest such cohort examined to date, and compared their results with 503 control participants of European ancestry.
A team of researchers in the laboratory of Dr. Ignatia Van den Veyver found that adult male offspring of female mice that were fed chronic low-protein diet are sluggish, with increased body fat and anxiety-like behaviors even though they were on a normal diet since weaning. The results of this study were published in the online journal PLoS One.
A ground-breaking study conducted in the lab of Dr. Hugo J. Bellen has now identified a novel signaling mechanism that allows for accumulation of LDs in glial cells causing neurodegeneration. Specifically, they found that dysfunction of neuronal mitochondria (cellular energy generator) cause excess lipids to accumulate in the neighboring glial cells (support cells) in fruit flies and mice.
For the first time, in a study published in Nature Neuroscience, researchers in the laboratory of Dr. Benjamin Arenkiel have demonstrated how inhibitory circuits form and develop in live brains. They made a surprising discovery that inhibitory circuits expand as they mature. Prior to this study, scientists had very little understanding of how sensory maps of inhibitory circuits develop or mature.
An international team led by Dr. Hugo J. Bellen, professor at Baylor College of Medicine and the Jan and Dan Duncan Neurological Research Institute (NRI) at Texas Children’s Hospital has identified a novel function for nardilysin, a mitochondrial protein, in the progressive degeneration of neurons. The study published in Neuron has utilized a relatively new multi-species genomics approach to provide a compelling genetic link between NRD1 and age-related neurodegeneration.
A study published in the journal eLife by Dr. Hugo J. Bellen’s team shows that loss of frataxin protein may cause neurodegeneration by accumulation of excess iron in mice and humans. In this study, the Bellen team led by graduate student Kuchuan Chen found that deletion of FXN in mice is similarly deleterious and leads to neurobehavioral defects. This study shows for the first time that loss of Fxn can lead to an accumulation of iron within the neuronal cell bodies and extracellular spaces of vertebrate brains.
A study published in the journal eLife from the laboratory of Dr. Huda Zoghbi has found a key regulator of two important proteins that have been implicated in various neurodegenerative diseases including Parkinson’s and Alzheimer’s. Excessive accumulation of alpha-synuclein and tau is believed to be the underlying cause of neurodegenerative conditions. This discovery opens up a new therapeutic strategy that could potentially in the future benefit patients suffering from certain neurodegenerative conditions.
A paper published this week in Neuron from Dr. Huda Y. Zoghbi’s laboratory shows that identical abnormalities in neural circuits might underlie similar features in two distinct genetic syndromes – Rett syndrome and MECP2 duplication syndrome. It was even more exciting that deep brain stimulation (DBS) reversed these circuit malfunctions in mouse models of Rett syndrome. The X-linked gene, MECP2, encodes methyl CpG-binding protein, a master regulator of several genes.
Drs. Shinya Yamamoto, Joshua M. Shulman and Hugo J. Bellen are part of a multi-center collaborative study that identified a novel genetic risk factor for late-onset Alzheimer’s disease (LOAD). Postdoctoral fellow, Dr. David Li-Kroeger, and graduate student, Jose Salazar, also contributed to the study published in the journal PLoS Genetics this week. This research illustrates how experiments performed in simple model organisms can complement human genetic discoveries.
In an exciting study published in the journal Neuron, Drs. Huda Zoghbi and Juan Botas have identified a kinase whose partial inhibition reduced aberrant tau aggregates and reversed memory deficits in a mouse model of neurodegeneration. In this study, researchers employed an innovative approach to identify novel genetic modifiers of tauopathy. They performed a stringent parallel cross-species screen of approximately 600 known kinases in a human cell line and fruit flies that overexpressed tau.
A seminal study published in Nature from the laboratory of Dr. Benjamin Arenkiel, associate professor at Baylor College of Medicine and researcher at the Neurological Research Institute at Texas Children's Hospital, demonstrates that a subset of cholinergic neurons in the basal forebrain act as critical regulators to modulate food intake and control body weight.
A paper published this week in Neuron from Dr. Huda Y. Zoghbi’s laboratory shows that identical abnormalities in neural circuits might underlie similar features in two distinct genetic syndromes – Rett syndrome and MECP2 duplication syndrome. It was even more exciting that deep brain stimulation (DBS) reversed these circuit malfunctions in mouse models of Rett syndrome.
A recent study published in the journal eLife by Dr. Hugo J. Bellen’s team at Baylor College of Medicine and Neurological Research Institute at Texas Children’s Hospital has provided the first experimental evidence that loss of frataxin may cause neurodegeneration via iron toxicity.
A team of researchers at the NRI led by Dr. Rodney Samaco characterized a novel genetic rat model of RTT that closely mimics many behavioral and molecular features of RTT patients. This study was published last week in the Human Molecular Genetics journal, with Dr. Surabi Veeraragavan. After confirming the rat model of RTT was missing the MeCP2 protein, the researchers set out to test the behavior of the animals, focusing on female rats.
In 2004 a team of researchers led by Dr. Huda Zoghbi, director of NRI and professor of molecular and human genetics at the Baylor College of Medicine, developed a mouse model for this duplication syndrome and hypothesized that excessive levels of MECP2 is the cause of the neurological symptoms observed in these patients. A year later the first individuals with duplication syndrome were diagnosed.
In a recent study published in Nature, a team of researchers have demonstrated that DBS of a specific area of the brain can revert learning and memory deficits in a mouse model of Rett syndrome, a leading cause of intellectual disability in girls. Although DBS has shown some promise in many movement disorders and neuropsychiatric disorders in children, this is the first experimental demonstration of the effectiveness of DBS in treating a childhood cognitive disorder.